Reg Anesth Pain Med:区域麻醉对乳腺癌手术术后复发、转移及免疫应答的影响;系统评价

2017-11-15 郭唯真 “罂粟花”微信号

围手术期是影响乳腺癌患者长期预后的重要时期。区域阻滞麻醉的使用,如椎旁阻滞(PVB),可能改善乳腺癌手术患者的长期预后。其机制主要是调节手术创伤造成的炎症反应和免疫反应,减少阿片类药物和全麻药物的使用量,通过局麻药的作用直接促进癌细胞死亡。

背景与目的:围手术期是影响乳腺癌患者长期预后的重要时期。区域阻滞麻醉的使用,如椎旁阻滞(PVB),可能改善乳腺癌手术患者的长期预后。其机制主要是调节手术创伤造成的炎症反应和免疫反应,减少阿片类药物和全麻药物的使用量,通过局麻药的作用直接促进癌细胞死亡。

方  法:系统检索行PVB的乳腺癌手术患者的研究。使用Jadad评分和Ottawa-Newcastle量表评估每项随机对照试验和观察性的回顾性研究的质量。只有高质量的研究被纳入荟萃分析。纳入的研究被分为3组来确定PVB的作用:(a)复发和生存,(b)体液免疫反应,(c)细胞免疫反应。

结  果:我们确定了467项相关研究,其中121篇阅读了标题和摘要,107篇被排除在外,15篇研究被纳入进行全文阅读和质量评估。由于存在低质量的研究,并且主要指标缺乏一致性,本文没有进行meta分析。因此,对现有的证据进行了系统评价。

结  论:我们的研究表明,没有证据证明PVB是否可以降低癌症复发或改善癌症相关生存。然而,与全麻和基于阿片类药物的镇痛相比,PVB与更低的炎症反应和更好的免疫反应相关。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2009481, encodeId=075c200948116, content=<a href='/topic/show?id=f97f33e8646' target=_blank style='color:#2F92EE;'>#区域麻醉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33786, encryptionId=f97f33e8646, topicName=区域麻醉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Sat Aug 11 01:02:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991815, encodeId=6aea1991815e3, content=<a href='/topic/show?id=ea25610484f' target=_blank style='color:#2F92EE;'>#术后复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61048, encryptionId=ea25610484f, topicName=术后复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Fri May 18 23:02:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050928, encodeId=3c0020509287c, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Aug 28 14:02:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400228, encodeId=cc11140022862, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Fri Nov 17 02:02:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444293, encodeId=f07b1444293ec, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Nov 17 02:02:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608249, encodeId=1620160824960, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Nov 17 02:02:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2009481, encodeId=075c200948116, content=<a href='/topic/show?id=f97f33e8646' target=_blank style='color:#2F92EE;'>#区域麻醉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33786, encryptionId=f97f33e8646, topicName=区域麻醉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Sat Aug 11 01:02:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991815, encodeId=6aea1991815e3, content=<a href='/topic/show?id=ea25610484f' target=_blank style='color:#2F92EE;'>#术后复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61048, encryptionId=ea25610484f, topicName=术后复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Fri May 18 23:02:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050928, encodeId=3c0020509287c, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Aug 28 14:02:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400228, encodeId=cc11140022862, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Fri Nov 17 02:02:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444293, encodeId=f07b1444293ec, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Nov 17 02:02:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608249, encodeId=1620160824960, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Nov 17 02:02:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2009481, encodeId=075c200948116, content=<a href='/topic/show?id=f97f33e8646' target=_blank style='color:#2F92EE;'>#区域麻醉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33786, encryptionId=f97f33e8646, topicName=区域麻醉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Sat Aug 11 01:02:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991815, encodeId=6aea1991815e3, content=<a href='/topic/show?id=ea25610484f' target=_blank style='color:#2F92EE;'>#术后复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61048, encryptionId=ea25610484f, topicName=术后复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Fri May 18 23:02:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050928, encodeId=3c0020509287c, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Aug 28 14:02:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400228, encodeId=cc11140022862, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Fri Nov 17 02:02:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444293, encodeId=f07b1444293ec, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Nov 17 02:02:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608249, encodeId=1620160824960, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Nov 17 02:02:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2009481, encodeId=075c200948116, content=<a href='/topic/show?id=f97f33e8646' target=_blank style='color:#2F92EE;'>#区域麻醉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33786, encryptionId=f97f33e8646, topicName=区域麻醉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Sat Aug 11 01:02:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991815, encodeId=6aea1991815e3, content=<a href='/topic/show?id=ea25610484f' target=_blank style='color:#2F92EE;'>#术后复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61048, encryptionId=ea25610484f, topicName=术后复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Fri May 18 23:02:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050928, encodeId=3c0020509287c, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Aug 28 14:02:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400228, encodeId=cc11140022862, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Fri Nov 17 02:02:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444293, encodeId=f07b1444293ec, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Nov 17 02:02:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608249, encodeId=1620160824960, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Nov 17 02:02:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2009481, encodeId=075c200948116, content=<a href='/topic/show?id=f97f33e8646' target=_blank style='color:#2F92EE;'>#区域麻醉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33786, encryptionId=f97f33e8646, topicName=区域麻醉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Sat Aug 11 01:02:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991815, encodeId=6aea1991815e3, content=<a href='/topic/show?id=ea25610484f' target=_blank style='color:#2F92EE;'>#术后复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61048, encryptionId=ea25610484f, topicName=术后复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Fri May 18 23:02:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050928, encodeId=3c0020509287c, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Aug 28 14:02:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400228, encodeId=cc11140022862, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Fri Nov 17 02:02:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444293, encodeId=f07b1444293ec, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Nov 17 02:02:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608249, encodeId=1620160824960, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Nov 17 02:02:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]
    2017-11-17 huagfeg
  6. [GetPortalCommentsPageByObjectIdResponse(id=2009481, encodeId=075c200948116, content=<a href='/topic/show?id=f97f33e8646' target=_blank style='color:#2F92EE;'>#区域麻醉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33786, encryptionId=f97f33e8646, topicName=区域麻醉)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Sat Aug 11 01:02:00 CST 2018, time=2018-08-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1991815, encodeId=6aea1991815e3, content=<a href='/topic/show?id=ea25610484f' target=_blank style='color:#2F92EE;'>#术后复发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61048, encryptionId=ea25610484f, topicName=术后复发)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=62e4433, createdName=zz12341234, createdTime=Fri May 18 23:02:00 CST 2018, time=2018-05-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050928, encodeId=3c0020509287c, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Tue Aug 28 14:02:00 CST 2018, time=2018-08-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1400228, encodeId=cc11140022862, content=<a href='/topic/show?id=10cc2901458' target=_blank style='color:#2F92EE;'>#免疫应答#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29014, encryptionId=10cc2901458, topicName=免疫应答)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a602256775, createdName=clmlylxy, createdTime=Fri Nov 17 02:02:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1444293, encodeId=f07b1444293ec, content=<a href='/topic/show?id=3d9291459d1' target=_blank style='color:#2F92EE;'>#评价#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=91459, encryptionId=3d9291459d1, topicName=评价)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1fee5134542, createdName=huagfeg, createdTime=Fri Nov 17 02:02:00 CST 2017, time=2017-11-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608249, encodeId=1620160824960, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Nov 17 02:02:00 CST 2017, time=2017-11-17, status=1, ipAttribution=)]

相关资讯

Anesth Essays Res:腹股沟疝修补术中脊髓麻醉和椎旁神经阻滞的比较

腹股沟疝修补术(IHR)是一种常见的外科手术,一般可在全麻、局部或周围神经阻滞麻醉下进行。我们研究的目的是比较椎旁神经阻滞(PVB)与脊髓麻醉(SA)对IHR术后镇痛,行走和不良反应的疗效。